Delivery Order SPE2DB20D7066-SPE2DB25FC4CF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,491.29 to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance, which aligns with AmerisourceBergen's corporate headquarters location. The delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,683.45 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in quantities of 90. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of July 29, 2025. This award represents a routine...
- The Defense Logistics Agency awarded a $17,169.05 delivery order to AmerisourceBergen Drug Corp for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contractor will perform fulfillment from its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a $5,910.20 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in quantities of 90 units. This firm fixed-price delivery order, which is not set-aside designated, is set to complete on July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a $2,162.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Losartan-HCTZ 50-12.5 mg tablets (90-count supply) on August 7, 2025, with a completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $19,748.97 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a quantity of 90 units. The contract employs firm fixed-price pricing with no set-aside designation and is scheduled for completion by July 28, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,400.84 for the supply of Losartan-HCTZ 100-12.5 mg tablets in 90-count packages. This contract, awarded on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Losartan-HCTZ 100-25 mg tablets in quantities of 1,000 units, with a contract ceiling value of $1,095.47. This firm fixed-price delivery order, which is set to be completed by July 23, 2025, represents a single-transaction pharmaceutical procurement from the company's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a quantity of 90 units, with a ceiling value of $2,609.93. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion on July 22, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,276.16 to AmerisourceBergen Drug Corp for 1,000 tablets of Losartan Potassium 100 mg, a commonly prescribed antihypertensive medication. The contract, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, utilizes firm fixed-price terms and requires performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award includes no set-aside designation and was competitively awarded through...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4CFDelivery Order
The Defense Logistics Agency awarded a $2,400.91 firm fixed price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Losartan-HCTZ 100-12.5 mg, a common antihypertensive medication combining a angiotensin II receptor blocker with a thiazide diuretic. The order was competitively awarded with no set-aside designation and is scheduled for completion by July 21, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at $999,999,999 and running through December 2026. The prime IDC serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally. Through this flexible contracting vehicle, AmerisourceBergen supplies critical pharmaceuticals and medical commodities to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 7/18/25 |